total MNC of 6.1 Â 10 8 /kg. Acute graft versus host disease (GVHD) prophylaxis was done with oral cyclosporine and methotrexate. Viral prophylaxis was done with acyclovir. Pneumocystis jirovecii prophylaxis was done with cotrimoxazole. Venooclusive disease prophylaxis was done with Ursodiol. Neutrophil engraftment occurred on day +14 and platelet engraftment occurred on day +24. Chimerism study of day +30 with VNTR showed 100% donor chimerism with normalization of CD18 expression.
At present, this patient is on uneventful follow-up for last 6 months. There was no acute GVHD or chronic GVHD.
While LAD-1 is due to lack of expression of CD18, LAD-2 is defect in expression of ligands for selectins due to lack of i n d i a n j o u r n a l o f t r a n s p l a n t a t i o n 9 ( 2 0 1 5 ) 1 6 2 - specific enzymes and LAD-3 is due to more than one variant of LAD. [1] [2] [3] [4] Generally, patients with severe LAD-1 (CD18 < 1%) succumb to life-threatening infection within 2 years of life. Those with milder forms (1-30% CD18) may survive till adulthood. There are no reported data of transplant outcomes in adults though the outcome in children is very good. The high rate of successful engraftment in LAD-1 is probably due to absence of CD11a/CD18 expression on lymphocytes. [1] [2] [3] [4] 
